Targeting FOXP3 Isoforms disrupts Tregs suppression in Colorectal Cancer 2259576
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.739 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Samantha Sharma und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
MSI-H colorectal cancer (CRC) displays a highly immunogenic TME. FOXP3+ Tregs are key mediators of immunosuppression within the TME. Notably, human FOXP3 exists as two major isoforms: the full-length (FOXP3FL) and an exon 2-skipped (FOXP3dE2), but the impact of FOXP3 isoform switching in CRC remains unexplored. We hypothesized that reprogramming tumor-infiltrating Tregs to express the FOXP3dE2 isoform would attenuate their immunosuppressive activity and enhance anti-tumor immunity.
Methods
We utilized a novel mouse model selectively expressing only the FOXP3ΔE2 isoform, allowing isoform-specific functional analyses without inducing global Treg depletion or autoimmunity. This model was employed to investigate the role of the FOXP3ΔE2 isoform in MC38-derived CRC tumors through both in vitro supression assay and in vivo tumor development studies.
Results
FOXP3dE2 mice showed increased Ki67+ Tregs, indicating higher proliferation. In vitro suppression assay revealed ∼80% reduced suppression of CD4 T-cell proliferation by tumor-infiltrating dE2 Tregs as compared to WT Tregs. In vivo, FOXP3dE2 mice exhibited enhanced anti-tumor immunity, with reduced tumor volumes and weights in the CRC mouse model. Further analysis revealed that FOXP3dE2 tumors exhibit significantly enhanced cytotoxic CD8 T cells with an increased proportion of CD8 T cells expressing IFN-γ and granzyme B.
Conclusion
These findings highlight the potential of targeting Treg isoforms to promote anti-tumor responses and offer a new approach for MSI-H CRC immunotherapy, potentially overcoming current ICB limitations while avoiding systemic autoimmunity. Funding Source n/a Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Zitieren
APA
Sharma, S., Singh, N., Zhou, B., Lu, X., & Zhang, X. (2026). Targeting FOXP3 Isoforms disrupts Tregs suppression in Colorectal Cancer 2259576. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.739
Vancouver
Sharma S, Singh N, Zhou B, Lu X, Zhang X. Targeting FOXP3 Isoforms disrupts Tregs suppression in Colorectal Cancer 2259576. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.739
BibTeX
@article{Sharma2026,
author = {Sharma, Samantha and Singh, Naresh and Zhou, Baohua and Lu, Xiongbin and Zhang, Xinna},
title = {Targeting FOXP3 Isoforms disrupts Tregs suppression in Colorectal Cancer 2259576},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.739}
}
EUVIMED